Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
Authors
Keywords
-
Journal
Journal of Diabetes Investigation
Volume 7, Issue -, Pages 80-86
Publisher
Wiley
Online
2016-04-03
DOI
10.1111/jdi.12446
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
- (2015) C. Brenner et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Glucagon-Like Peptide-1 Receptor Activation Does Not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury
- (2015) Linnea Eriksson et al. JOURNAL OF VASCULAR RESEARCH
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
- (2015) Jixin Zhong et al. Journal of Diabetes Research
- Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
- (2014) Julie A. Lovshin et al. Canadian Journal of Diabetes
- Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
- (2014) Yuichi Terawaki et al. Cardiovascular Diabetology
- The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
- (2014) Yanmei Zeng et al. Cardiovascular Diabetology
- Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
- (2014) Angelo Avogaro et al. CURRENT PHARMACEUTICAL DESIGN
- Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits
- (2014) Manar A. Nader NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
- (2014) Yuko Tashiro et al. PEPTIDES
- DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway
- (2013) Yao Dai et al. ACTA DIABETOLOGICA
- Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins
- (2013) Masashi Shiomi et al. ATHEROSCLEROSIS
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
- (2013) Nasib Ervinna et al. ENDOCRINOLOGY
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes
- (2013) Tetsurou Ikeda et al. PLoS One
- Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
- (2013) Michishige Terasaki et al. PLoS One
- Human Apolipoprotein A-II Protects Against Diet-Induced Atherosclerosis in Transgenic Rabbits
- (2012) Yao Wang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
- (2012) Jixin Zhong et al. ATHEROSCLEROSIS
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice
- (2012) F. Vittone et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury
- (2012) Yoichiro Hirata et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of PKF275-055, a dipeptidyl peptidase–4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E–null mice
- (2012) Michishige Terasaki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
- (2012) Yukinori Nogi et al. PLoS One
- Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
- (2012) Soo Lim et al. PLoS One
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
- (2011) Hiromasa Goto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
- (2011) Nga N Ta et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Acyl-coenzyme A:cholesterol acyltransferases
- (2009) Ta-Yuan Chang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started